Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma
Por:
Sorigue, M and Kuittinen, O
Publicada:
3 jul 2021
Ahead of Print:
1 jul 2021
Resumen:
Background: Results of randomized clinical trials may not be entirely applicable to clinical practice. The present manuscript aims to explore the pragmatism and robustness of the evidence that supports the European Society for Medical Oncology (ESMO) follicular lymphoma (FL) guidelines. Methods & design: Analysis of all trials used to support positive, therapeutic, oncological recommendations in the 2020 ESMO FL guidelines. Predefined data points were extracted from each trial. Pragmatism was assessed by means of the PRECIS-2 tool, the difference in overall survival in the interventions compared and the source of funding. Robustness was assessed by means of the fragility index and the p value. Results: 28 trials were included. The full protocol or a protocol summary was provided for 12 (43%). Based on the PRECIS-2 domains, trials were considered pragmatic in organization, analysis and flexibility and explanatory in eligibility. Robustness was high, with 4/24 (17%) trials with p values between 0.05 and 0.005 and a median fragility index of 18. Conclusions: Results of trials to support ESMO recommendations in FL were robust. Pragmatism was high in some domains but modest to low in others and the pattern was similar across trials. Transparency in the publication of trial protocols was suboptimal.
Filiaciones:
:
UAB, ICO IJC Hosp Germans Trias & Pujol, LUMN, Dept Hematol, Badalona, Spain
Kuittinen, O:
Oulu Univ Hosp, Dept Oncol & Radiotherapy, Kuopio, Finland
Univ Eastern Finland, Fac Hlth Med, Inst Clin Med, Kuopio, Finland
Kuopio Univ Hosp, Dept Oncol, Kuopio, Finland
|